US doctors reconsider Pfizer’s Paxlovid for low-risk COVID patients

May 28 (Reuters) – Use of Pfizer Inc. (PFE.N) COVID-19 antiviral Paxlovid peaked this week, but some doctors are reconsidering the pills for low-risk patients after a US public health agency warned symptoms may return after people finish treatment with the drug, and that they should then self-isolate a second time. More quarantine time “is …

US doctors reconsider Pfizer’s Paxlovid for low-risk COVID patients Read More »